• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: TERUMO CORPORATION, ASHITAKA CAPIOX FX OXYGENATOR; OXYGENATOR, CARDIOPULMONARY BYPASS

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

TERUMO CORPORATION, ASHITAKA CAPIOX FX OXYGENATOR; OXYGENATOR, CARDIOPULMONARY BYPASS Back to Search Results
Catalog Number CX-XRY32302
Device Problem Infusion or Flow Problem (2964)
Patient Problem No Consequences Or Impact To Patient (2199)
Event Date 08/28/2018
Event Type  malfunction  
Manufacturer Narrative
Implanted date: device was not implanted.Explanted date: device was not explanted.510(k): k130520.The actual device was returned for evaluation.Visual inspection revealed no anomalies, such as a break, in the appearance.Saline solution was let to flow through the actual device by gravity.Another unaided visual inspection of the actual device revealed no clot formation.The actual device was fixed with saline solution containing glutaraldehyde solution.Subsequent visual inspection, after the housing component had been removed, did not reveal any clots on the outer surface of the filter.The filter was removed from the oxygenator module for further visual inspection.No formation of clots was revealed on the outer or inner surface.Unaided visual inspection of the oxygenator module did not reveal any formation of clots.The fiber winding was confirmed to be in the normal state.The fiber layer was removed from the winding in increments of 2mm and each layer was subjected to visual inspection.There was no clot formation that was visible with the naked eye on the fiber.The fiber and the outer cylinder were removed from the heat exchanger module and the inside of the heat exchanger module was subjected to visual and magnifying inspections.No formation of clots was revealed.The filter was removed from the oxygenator module in above test and was inspected under magnification.No formation of clots was revealed.The fiber layers removed during the test in above no.6 were inspected under magnification.No formation of clots was observed.The filter removed from the oxygenator module in above no.4 was inspected under electron microscope.The adhesion of a slight amount of erythrocyte components was revealed.Electron microscopic inspection of the fiber on each layer on the upper side of the fiber winding obtained in the above test revealed the adhesion of a slight amount of erythrocyte components, including red blood cells, white blood cells and platelets, on the fiber.A review of the device history record of the involved product code/lot number combination revealed no findings.A search of the complaint file found no previous report of this nature with the involved product /lot# combination.There is no evidence that this event was related to a device defect or malfunction.During the inspection of the actual device, the adhesion of a slight amount of erythrocyte components was revealed.However, it cannot be determined if this had any cause-and -effect relationship with the reported deterioration of the gas transfer performance.(b)(4).
 
Event Description
The user facility reported that the actual sample was used on the patient with the body surface area ,1.8m squared in a total arch replacement.After de-clamping, o2 addition quickly started to fail to catch up with the required volume.With fio2=100%, pao2 went to 80mmhg.Gas flow rate=5l/min., and the blood flow rate=4.8l/min., also with no anomaly in act or in the pressure inside the circuit, pao2 went down to 80mmhg.The patient was weaned from the pump safely.The actual sample was not changed out.There was no blood loss.There was no harm to the patient.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
CAPIOX FX OXYGENATOR
Type of Device
OXYGENATOR, CARDIOPULMONARY BYPASS
Manufacturer (Section D)
TERUMO CORPORATION, ASHITAKA
150 maimaigi-cho
fujinomiya city, shizuoka 418
JA  418
Manufacturer (Section G)
TERUMO CORPORATION, ASHITAKA
reg. no. 9681834
150 maimaigi-cho
fujinomiya city, shizuoka 418
JA   418
Manufacturer Contact
mark vornheder
reg. no. 2243441
950 elkton blvd
elkton, MD 21921
8002837866
MDR Report Key7884804
MDR Text Key120740123
Report Number9681834-2018-00158
Device Sequence Number1
Product Code DTZ
Combination Product (y/n)N
Reporter Country CodeJA
PMA/PMN Number
K071494
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,foreig
Reporter Occupation Other Health Care Professional
Type of Report Initial
Report Date 09/18/2018
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date08/31/2019
Device Catalogue NumberCX-XRY32302
Device Lot Number180329
Was Device Available for Evaluation? Device Returned to Manufacturer
Date Returned to Manufacturer09/03/2018
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 08/30/2018
Initial Date FDA Received09/18/2018
Was Device Evaluated by Manufacturer? Yes
Date Device Manufactured03/29/2018
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
-
-